Q1 2022 results - Tuesday, April 26, 2022
|Excluding Roche investment impacts2||Reported|
|Net sales||12,531||12,411||1 (cc: 5)||12,411||1 (cc: 5)|
|Operating income||2,852||2,415||18 (cc: 26)||2,415||18 (cc: 26)|
|Net income||2,219||1,803||23 (cc: 32)||2,059||8 (cc: 15)|
|EPS (USD)||1.00||0.80||25 (cc: 34)||0.91||10 (cc: 17)|
|Free cash flow||920||1,075||-14||1,597||-42|
|Operating income||4,083||3,957||3 (cc: 9)||3,957||3 (cc: 9)|
|Net income||3,251||3,100||5 (cc: 11)||3,413||-5 (cc: 0)|
|EPS (USD)||1.46||1.38||6 (cc: 12)||1.52||-4 (cc: 2)|
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
- A reconciliation of 2021 IFRS results and non-IFRS measures core results and free cash flow to exclude the impacts of the 2021 divestment of our Roche investment can be found on page 40 of the Condensed Interim Financial Report. The free cash flow impact represents the dividend received in Q1 2021 from Roche in relation to the distribution of its 2020 net income.